WINT vs. SQZ, TCBP, SCNI, ELOX, NSTGQ, ALBT, PALI, KRBP, FNCH, and SRNE
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include SQZ Biotechnologies (SQZ), TC Biopharm (TCBP), Scinai Immunotherapeutics (SCNI), Eloxx Pharmaceuticals (ELOX), NanoString Technologies (NSTGQ), Avalon GloboCare (ALBT), Palisade Bio (PALI), Kiromic BioPharma (KRBP), Finch Therapeutics Group (FNCH), and Sorrento Therapeutics (SRNE). These companies are all part of the "biological products, except diagnostic" industry.
SQZ Biotechnologies (NYSE:SQZ) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
In the previous week, Windtree Therapeutics had 7 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 7 mentions for Windtree Therapeutics and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.61 beat Windtree Therapeutics' score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the news media.
Windtree Therapeutics has a net margin of 0.00% compared to Windtree Therapeutics' net margin of -369.96%. Windtree Therapeutics' return on equity of -119.83% beat SQZ Biotechnologies' return on equity.
Windtree Therapeutics has lower revenue, but higher earnings than SQZ Biotechnologies. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Comparatively, 0.5% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
SQZ Biotechnologies received 7 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave SQZ Biotechnologies an outperform vote while only 50.00% of users gave Windtree Therapeutics an outperform vote.
Summary
SQZ Biotechnologies beats Windtree Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Windtree Therapeutics Competitors List
Related Companies and Tools